Optimising the Management of ADHD. Dr Khalid Karim University of Leicester Leicestershire Partnership Trust

Similar documents
Intelligent Prescribing. Optimizing Medication Treatments in ADHD Dr Dave Coghill

Adult Neurodevelopmental Services. ADHD Shared Protocol

ADHD. Medicines to help symptoms of adult attention deficit hyperactivity disorder (ADHD)

Behavioural interventions for ADHD.

MRCPsych Pharmacology of ADHD treatment. Dr Xanthe Barkla, Consultant Child and Adolescent Psychiatrist

ASD and ADHD predictably unpredictable Nothing seems to work

Dr S H Jawed Consultant General Adult Psychiatrist, Dorothy Pattison Hospital, Walsall Joint Lead Consultant for

European Network for Hyperkinetic Disorders EUNETHYDIS

Attention Deficit Hyperactivity Disorder

Issue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist

ADHD Training for General Practitioners

ASD and ADHD predictably unpredictable Nothing seems to work

ADHD Explanation 5: Medications used in ADHD

Attention Deficit Hyperactive Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

SHARED CARE PRESCRIBING GUIDELINE

Scottish Medicines Consortium

How is standard ADHD medication used in clinical practice and how is this supported by research?

If a specialist asks a GP to prescribe ADHD medication in relation to this disease, the GP should reply to this request as soon as practicable.

THE SCHOOL SETTING INCLUDING THE ROLE OF COMMUNITY CHILD HEALTH MEDICAL AND SCHOOL NURSING SERVICES

Disclosures. Speakers and Consultancy fees from. Lundbeck Janssen Eli Lilly

Outline & Objectives

ADHD in Adults Service Development

ATOMOXETINE AND METHYLPHENIDATE TREATMENT IN ADHD

Attention Deficit Hyperactivity Disorder (ADHD) BY MARK FABER M.D.

Holistic approach in management of ADHD

AD/HD is a mental disorder, and it often lasts from

Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement

Attention deficit hyperactivity disorder (update)

Preliminary Report on the Impact of Smartglasses-based Behavioral and Social Communication Aid on Hyperactivity in Children and Adults with Autism.

NCMH National Centre for Mental Health Attention Deficit Hyperactivity Disorder (ADHD) Information for parents, carers and children

Press Release

SHARED PRESCRIBING GUIDELINE

Drug Class Review. Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder

PAL Conference Cle Elum March 2015

Attention Deficit Hyperactivity Disorder Overview and New Perspectives

Medications in Autism: What We Know and Don't Know

ADHD and Substance Use Disorders: An Intoxicating Combination

GM ADHD Strategic Clinical Network. Training for Specialist ADHD Teams

METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE

Adult ADHD: How Big is the Problem? Delivering Effective Services for Adults with ADHD

2017/2018 ADHD Guidelines: A Summary of Recommendations for Pharmacological Treatment From Selected Guidelines

35 mg NF -- Dextroamphetamine Sulfate IR Tablets: Zenzedi IR Ttablets: Dextroamphetamine Sulfate ER Capsules: 15 mg ProCentra Solution.

Attention Deficit Hyperactivity Disorder (ADHD) in Children under Age 6

MEDICINES MANAGEMENT FOR ADULT ADHD GLOUCESTERSHIRE PATHWAY. Before commencing treatment measure weight, blood pressure and heart rate.

SHARED CARE GUIDELINE

Adult ADHD How Big is the Problem? National Perspective

Topic proposal. 1. What is the problem/need for a guideline/clinical scenario?

A guide to Getting an ADHD Assessment as an adult in Scotland

PRACTICE PARAMETERS FOR THE ASSESSMENT AND TREATMENT OF CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER

Medication in attention deficit hyperactivity disorder and adhd with Autistic Spectrum Disorder (ASD)

EIF PROGRAMME REPORT THE NEW FOREST PARENTING PROGRAMME

Attention-Deficit/Hyperactivity Disorder Nathan J. Blum, M.D.

Clinical assessment of ADHD. The size of a clinic s problem. Diagnosis: detecting the disorder. ADHD has several components

Attention deficit hyperactivity disorder

Adult ADHD - New Models of Care

IELTS Academic Reading Sample A.D.D. Missing Out on Learning

Managing Tourette Syndrome

BRIEF. Attention-Deficit/Hyperactivity Disorder SEPTEMBER Diagnosis

CAMHS. Your guide to Child and Adolescent Mental Health Services

NICE quality standard for attention deficit hyperactivity disorder (QS39)

Bournemouth, Dorset and Poole Prescribing Forum

National Institute for Health and Clinical Excellence. Clinical guideline: ADHD PRE-PUBLICATION CHECK

To Give or not to Give Medication: That is the Question

Bournemouth, Dorset and Poole Prescribing Forum

Pharmacotherapy for Attention-deficit Hyperactivity Disorder

Behavioral Health. Behavioral Health. Prescribing Guidelines

What are the most common signs of ADHD? And what are the most common medication interventions?

Pharmacotherapy of ADHD with Non- Stimulants

The Quality of Life of Children with Attention Deficit/Hyperactivity Disorder and. Related Disorders: A Systematic Review

Adult ADHD Service Development. Dr Joe Johnson Consultant Psychiatrist Five Boroughs Partnership NHS Trust

McCarthy, S; Wilton, L; Murray, ML; Hodgkins, P; Asherson, P; Wong, ICK

What is Tourette Syndrome?

The Liverpool Asperger Team

POsitive mental health for young people. What you need to know about Children and Adolescent s Mental Health Services (CAMHS) in Buckinghamshire

Stimulants are widely prescribed as a treatment for

Contents Definition and History of ADHD Causative Factors

London Medicines Information Service

abstract CLINICAL PRACTICE GUIDELINE FROM THE AMERICAN ACADEMY OF PEDIATRICS

AD/HD and co-existing conditions an overview

Discussion. What phrase best describes your beliefs about a diagnosis of AD(H)D in adults? Unconvinced Sceptical Open-minded Accepting Unsure

Protocol 02, v1.0, HMMC October of 22

Strathprints Institutional Repository

Atomoxetine (First known as Tomoxetine) (Adopted by the CCG until review and further notice)

LMMG New Medicine Recommendation

ADHD training Accident and Emergency

Lisa Goldstein, MD Child and Adolescent and Adult Psychiatrist

The Benefits and Limitations of Medication Treatment for Executive Dysfunctions and ADHD

MANAGEMENT OF ADHD IN ADULTS

Treating Disruptive Behavior Disorders in Children and Teens. A Review of the Research for Parents and Caregivers

ATTENTION DEFICIT HYPERACTIVITY DISORDER COMORBIDITIES 23/02/2011. Oppositional Defiant Disorder

The Use of ADHD Medication in the Pediatric Population

Diagnosis and management of ADHD in children and adults

Prevalence of Comorbidity and Pattern Drug Use among Children with Attention-deficit hyperactivity disorder: A Single Center in Thailand

How has acceptability of healthcare interventions been defined and assessed? An overview of Systematic Reviews

About ADHD. National Resource Center on ADHD A Program of CHADD

WARNING LETTER TRANSMITTED BY FACSIMILE

Mental Health Strategy. Easy Read

NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng87

Transcription:

Optimising the Management of ADHD Dr Khalid Karim University of Leicester Leicestershire Partnership Trust

Declaration Have previously presented talks and workshops for Shire Janssen Lilly Flynn I have not received any other funding This talk is a reflection of the available literature and personal opinion

Real title Is it actually possible to optimise ADHD treatment? Or a typical NHS fantasy Is it possible to quantify improvement? Use of rating scales

Aim To think about what we mean by optimising treatment of ADHD in practice Consider the various factors which affect this possibility Explore the various options when addressing this problem

Optimising Treatment Optimising make the best or most effective use of (a situation or resource) Google to make something as good as possible Cambridge Dictionary Treatment (Google) the manner in which someone behaves towards or deals with someone or something care given to a patient for an illness or injury

Optimising Treatment Why is it so difficult? Should we be trying to do this? Is there any way to do this? Would we know when we have got there? Who are we doing it for?

Who are we treating? The child/young person/adult with ADHD The parents/carers/others The education provision Social care provision Healthcare/justice system/employers

Who are we treating? There may be conflicting views on what are the issues Symptoms may change over time/developmental The child/young person will develop their own view/ independence May not want to take treatment/see the point What goals do we set with these different interest groups? Clinicians?

Clinician issues What pressure are services under so is optimisation even possible? Referral numbers Staff availability Clinical training and understanding Clinic time Service design Availability of treatment options (vary enormously) Psycho-education Behavioural management Pharmacological

What are we treating to get optimisation? Attention/concentration Impulsivity Hyperactivity Executive functioning Emotional volatility Anxiety Self-esteem Motor function difficulties Autistic tendencies Substance misuse Tics

What are we treating? The observed presentation Tends to dominate situations The inner cognitive presentation Behaviours are only a marker of these thoughts and feelings Risk profile

Why should we try to optimise treatments? Shaw et al (2012) Systemic review- improvements in many areas but some better than others compared with untreated ADHD- not necessarily optimised Still limited evidence Fredriksen et al (2013) Stimulant medication and atomoxetine generally well tolerated Fairly short studies, limited longer-term evidence Negative outcomes with untreated ADHD Multiple outcomes

Pragmatic approach Treatment in contemporary practice adopts SMART solutions Particularly being measurable Dundee ADHD care pathway (Coghill 2015) Clinical feedback, ADHD-RS-IV,SNAP-IV, SKAMP, CGAS I would argue that ADHD is more complex Limitations of instruments If we treat one thing something else changes Unpredictable outcomes least worse option Balance of outcome/side effects/compliance/engagement

ADHD is not a constant Optimisation of a moving target Child growth Child cognitive development Changes in the brain-up to 25yrs Inconsistency of symptoms on daily basis Effects of sleep, hunger, fatigue Effects of anxiety etc, etc.

What could we try? Feel free to come up with any suggestions NICE guidelines 2008 (updated 2016) Moderate Parent education Group parenting/cbt or individual CBT/social skills Then medication Severe Medication first Group/individual interventions Considerably affected by the resources available: TIME/staff/funding

What could we try? Executive Functioning Increasingly important in adolescence/adulthood Measurable- BRIEF Limited evidence of effectiveness of cognitive training (Rapport et al 2013) Medication-some limited evidence/?higher doses Sleep Significant data on sleep problems in ADHD Brief sleep intervention (Hiscock 2015)most on ADHD treatment Worse sleep on stimulant medication (Kidwell et al 2015) Use of melatonin for sleep issues

What could we try? Do behavioural interventions help? Literature is a little conflicting Daley et al (2014) meta-analysis No effect on core symptoms Effect on parenting and conduct behaviour Anxiety problems Sciberras, et al (2014) Occur in up to 40% children with ADHD Aetiology unclear but does affect presentation and treatment Focus on emotional dysregulation

Medication Remains controversial for many Fairly good evidence Short acting methylphenidate/dexamphetamine Longer acting methylphenidate (Equasym XL, Concerta XL, Medikinet XL Lisdexamfetamine (Elvanse) Atomoxetine (Stattera) Guanfacine (Intuniv) prolonged release Non-standard unlicensed treatments Imipramine, Clonidine

Optimising medication Significant evidence medication effective Longer-term effectiveness? Limited comparative data Farone (2010) compared stimulants Hanwella (2011) atomoxetine vs stimulants Guanfacine (intuniv) limited available data Effectiveness vs side-effects Analogy to OCD treatment (medication and therapy)

In Practice Essential to develop a comprehensive understanding of ADHD, there are limited training opportunities however. Essential to develop a good therapeutic relationship with the child and carers Consider with non-medical staff with some adolescents Consider what is the actual understanding of ADHD as child grows Profile changes, less hyperactivity, independence skills, ASD symptoms Warn in advance of the need to chop and change Careful with expectations

In Practice Decide on goals of treatment and tailor options to this Let family/young person decide on option (if possible) Assess for a number of changes Behaviour Attention Executive functioning Emotional changes Versus side-effects for medication Multidisciplinary group Training in ADHD, medication, CBT(anxiety)Sleep

In practice The treatment level is dependent on feedback from the child, family and school Fairly low threshold for medication/changing medication Examples of practice High levels of methylphenidate trialled on Lisdexamfetamine Longer acting stimulants for older children Emotional volatile-24 hour treatments Changing treatments for tics, appetite, sleep Medication differences in holidays/weekends/daily

Some complexities ADHD and ASD ADHD and Tics ADHD and epilepsy Presentations according to gender

Summary There appears to be no easy way to optimise medication Many different competing factors Understanding ADHD and the treatments appears to be a sensible option TIME is a critical element Questions?

References Shaw, M., Hodgkins, P., Caci, H., Young, S., Kahle, J., Woods, A.G. and Arnold, L.E., 2012. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC medicine, 10(1), p.99. Fredriksen, M., Halmøy, A., Faraone, S.V. and Haavik, J., 2013. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. European Neuropsychopharmacology, 23(6), pp.508-527. Rittel, H.W. and Webber, M.M., 1973. 2.3 planning problems are wicked. Polity, 4, pp.155-169. Attention deficit hyperactivity disorder: diagnosis and management NICE 2016 https://www.nice.org.uk/guidance/cg72 Rapport, M.D., Orban, S.A., Kofler, M.J. and Friedman, L.M., 2013. Do programs designed to train working memory, other executive functions, and attention benefit children with ADHD? A meta-analytic review of cognitive, academic, and behavioral outcomes. Clinical psychology review, 33(8), pp.1237-1252. Hiscock, H., Sciberras, E., Mensah, F., Gerner, B., Efron, D., Khano, S. and Oberklaid, F., 2015. Impact of a behavioural sleep intervention on symptoms and sleep in children with attention deficit hyperactivity disorder, and parental mental health: randomised controlled trial. bmj, 350, p.h68. Kidwell, K.M., Van Dyk, T.R., Lundahl, A. and Nelson, T.D., 2015. Stimulant medications and sleep for youth with ADHD: a metaanalysis. Pediatrics, pp.peds-2015. Daley, D., Van der Oord, S., Ferrin, M., Danckaerts, M., Doepfner, M., Cortese, S., Sonuga-Barke, E.J. and European ADHD Guidelines Group, 2014. Behavioral interventions in attention-deficit/hyperactivity disorder: a meta-analysis of randomized controlled trials across multiple outcome domains. Journal of the American Academy of Child & Adolescent Psychiatry, 53(8), pp.835-847.

References Cortese, S., Holtmann, M., Banaschewski, T., Buitelaar, J., Coghill, D., Danckaerts, M., Dittmann, R.W., Graham, J., Taylor, E. and Sergeant, J., 2013. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. Journal of Child Psychology and Psychiatry, 54(3), pp.227-246. Faraone, S.V. and Buitelaar, J., 2010. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. European child & adolescent psychiatry, 19(4), pp.353-364. Hanwella, R., Senanayake, M. and de Silva, V., 2011. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC psychiatry, 11(1), p.176. Coghill, D. and Seth, S., 2015. Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway. Child and adolescent psychiatry and mental health, 9(1), p.52. Sciberras, E., Lycett, K., Efron, D., Mensah, F., Gerner, B. and Hiscock, H., 2014. Anxiety in children with attention-deficit/hyperactivity disorder. Pediatrics, 133(5), pp.801-808.